PrimeC continues to slow ALS progression: One-year trial data

Amyotrophic lateral sclerosis (ALS) patients who used NeuroSense Therapeutics‘ investigational therapy PrimeC for a year saw significantly slower disease progression and prolonged survival relative to patients who started the treatment six months later. That’s according to one-year findings from the PARADIGM Phase 2b clinical trial (NCT05357950),…

An advisory committee of the European Medicines Agency (EMA) has recommended against granting conditional marketing authorization to masitinib as an oral add-on treatment for amyotrophic lateral sclerosis (ALS). The negative opinion by the Committee for Medicinal Products for Human Use (CHMP) confirms the committee’s view, announced last…

Being diagnosed with ALS felt like a crushing blow to Craig. As a former band director who mentored students, he knew his life would change. Discover how Craig found his new purpose and community to inspire.

BrainStorm Cell Therapeutics has reached an alignment with the U.S. Food and Drug Administration (FDA) on the chemistry, manufacturing, and controls aspects — known as CMC — of the company’s upcoming Phase 3b trial of NurOwn (debamestrocel), to be tested in people with amyotrophic lateral sclerosis (ALS). This…

In amyotrophic lateral sclerosis (ALS), nerve cells in the spinal cord responsible for inhibiting motor neurons are lost in the early stages of the disease, before the motor neurons themselves, according to a new study done in a genetic mouse model of ALS. The researchers also found that excitatory…

On my first date with my late husband, Jeff, he rhapsodized about his family. He was the middle child of seven, and it was clear from the start that his brothers and sisters were a central part of his life. They’d grown up together in a home in Wyandotte, Michigan,…

I’m cautious about leaving my husband, Todd, alone because ALS has compromised his lung function. Todd can usually tell when mucus starts building up, so if his lungs are doing well, we’re comfortable with me running errands or attending events, as long as I’m not more than 15 minutes…

Treatment with fasudil (RT1968), which Raya Therapeutic is testing for amyotrophic lateral sclerosis (ALS), was safe and outperformed a placebo at preserving motor neurons in adults with early-stage disease. That’s according to data from ROCK-ALS (NCT03792490), an investigator-led Phase 2a trial that tested how safe fasudil is…